8 terminated. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Terminated 8 |
| Phase 2 | 4 | Terminated 4 |
Follow Urticaria: new trials by email Literature Review of Urticaria trials Research Report on Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines Briquilimab - Chronic Inducible Urticaria | Phase 1 / Phase 2 | Terminated | Jasper Therapeutics, Inc. | 27 | 2024-03-18 | 2025-10-08 |
| Study of Mechanism of Action of Ligelizumab (QGE031) in Patients With Chronic Urticaria Ligelizumab, Placebo - Chronic Spontaneous Urticaria, Cholinergic Urticaria | Phase 1 | Terminated | Novartis Pharmaceuticals | 11 | 2020-08-05 | 2024-06-18 |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants UCB8600, Placebo - Healthy Study Participants, Chronic Spontaneous Urticaria | Phase 1 | Terminated | UCB Biopharma SRL | 40 | 2020-06-30 | 2022-07-19 |
| A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults PF-05180999, Placebo, 120 mg MR PF-05180999 - Migraine | Phase 1 | Terminated | Pfizer | 31 | 2014-01-01 | 2014-05-08 |
| Bradykinin Receptor Blocker in ACE Inhibitor-associated Angioedema HOE-140, Placebo - Angioneurotic Edema | Phase 1 | Terminated | Vanderbilt University | 13 | 2007-09-01 | 2015-12-18 |
| Safety Study of Rituximab (Rituxan®) in Chronic Urticaria Rituximab - Urticaria | Phase 1 / Phase 2 | Terminated | Johns Hopkins University | 15 | 2006-01-01 | 2015-09-02 |
| Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease anakinra - Nervous System Malformations, Arthropathy, Neurogenic | Phase 1 / Phase 2 | Terminated | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 43 | 2003-09-01 | 2016-12-01 |
| Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions UVA1 Irradiation, UVB Irradiation - Atopic Dermatitis, Psoriasis | Phase 1 / Phase 2 | Terminated | University of Michigan | 28 | 2000-08-01 | 2015-05-22 |
Chronic Urticaria (3) · Chronic Inducible Urticaria (2) · Skin Diseases (2) · Alopecia (1) · Angioedema (1) · Arthropathy, Neurogenic (1) · Cold Urticaria (1) · Congenital Abnormalities (1) · Cryopyrin-Associated Periodic Syndromes (1) · Dermatitis, Atopic (1) · Immune System Diseases (1) · Joint Diseases (1) · Lymphoma, T-Cell, Cutaneous (1) · Migraine Disorders (1)
Hypersensitivity (8) · Hypersensitivity, Immediate (8) · Skin and Connective Tissue Diseases (8) · Immune System Diseases (7) · Skin Diseases, Vascular (7) · Skin Diseases (6) · Pathological Conditions, Signs and Symptoms (5) · Chronic Disease (4) · Disease Attributes (4) · Pathologic Processes (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Nervous System Diseases (2) · Signs and Symptoms (2) · Skin Diseases, Genetic (2)
Cetirizine (1) · Interleukin 1 Receptor Antagonist Protein (1) · Rituximab (1) · icatibant (1) · ligelizumab (1)
Jasper Therapeutics, Inc. (1) · Johns Hopkins University (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Novartis Pharmaceuticals (1) · Pfizer (1) · UCB Biopharma SRL (1) · University of Michigan (1) · Vanderbilt University (1)
United States (5) · Germany (2) · Bulgaria (1)
Clifton O. Bingham, III, MD (1) · John J Voorhees, MD (1) · Nancy J. Brown, MD (1) · Raphaela T Goldbach-Mansky, M.D. (1)
PMID 12384926, PMID 15201414, PMID 15334472, PMID 16899778, PMID 18645136, PMID 22294344, PMID 25223501, PMID 27143789, PMID 28118536
2019 (2), 2023 (1), R01HL079184 (1), ZIAAR041138-08 (1)